Clinical study of needle knife tendon thinning and unbinding in the treatment of adhesive shoulder bursitis in painful period

注册号:

Registration number:

ITMCTR2100005383

最近更新日期:

Date of Last Refreshed on:

2021-12-07

注册时间:

Date of Registration:

2021-12-07

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刀疏筋解结术治疗疼痛期粘连性肩关节囊炎的临床研究

Public title:

Clinical study of needle knife tendon thinning and unbinding in the treatment of adhesive shoulder bursitis in painful period

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刀疏筋解结术治疗疼痛期粘连性肩关节囊炎的临床研究

Scientific title:

Clinical study of needle knife tendon thinning and unbinding in the treatment of adhesive shoulder bursitis in painful period

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100054027 ; ChiMCTR2100005383

申请注册联系人:

王若州

研究负责人:

王海东

Applicant:

Wang Ruozhou

Study leader:

Wang Haidong

申请注册联系人电话:

Applicant telephone:

18219816751

研究负责人电话:

Study leader's telephone:

15002591581

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1577466304@qq.com

研究负责人电子邮件:

Study leader's E-mail:

whaidong5895@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

甘肃省兰州市城关区定西东路35号甘肃中医药大学

研究负责人通讯地址:

甘肃省兰州市七里河区瓜州路418号甘肃省中医院

Applicant address:

Gansu University of traditional Chinese Medicine, 35 Dingxi East Road, Chengguan District, Lanzhou City, Gansu Province

Study leader's address:

418 Guazhou road, Qilihe district, Lanzhou city, Gansu province, Gansu province traditional Chinese medicine hospital

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

甘肃中医药大学

Applicant's institution:

Gansu University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021-031-02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

甘肃省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Gansu Provincial Hospital of traditional Chinese medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021/3/31 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

甘肃省中医院

Primary sponsor:

Gansu provincial hospital of traditional Chinese medicine

研究实施负责(组长)单位地址:

甘肃省兰州市七里河区瓜州路418号甘肃省中医院

Primary sponsor's address:

418 Guazhou road, Qilihe district, Lanzhou city, Gansu province, Gansu province traditional Chinese medicine hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

甘肃省

市(区县):

Country:

China

Province:

Gansu province

City:

单位(医院):

甘肃省中医院

具体地址:

甘肃省兰州市七里河区瓜州路418号甘肃省中医院

Institution
hospital:

Gansu provincial hospital of traditional Chinese medicine

Address:

418 Guazhou road, Qilihe district, Lanzhou city, Gansu province, Gansu province traditional Chinese medicine hospital

经费或物资来源:

导师科研经费支持

Source(s) of funding:

The financial support of the tutor’s scientific research

研究疾病:

粘连性肩关节囊炎

研究疾病代码:

Target disease:

Adhesive Bursitis of shoulder

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

I期临床试验

Phase I clinical trial

研究目的:

本研究以“经筋理论”为依据,采用随机对照试验,通过与肩关节腔皮质类固醇注射对照,观察针刀疏筋解结术治疗疼痛期粘连性肩关节囊炎的临床疗效,为临床上运用中医经筋理论指导针刀治疗粘连性肩关节囊炎提供新思路和新方法。

Objectives of Study:

Based on the "Meridian tendon Theory", a randomized controlled trial was conducted to observe the clinical efficacy of needle knife in the treatment of adhesive shoulder bursitis in the period of pain by comparing with corticosteroid injection in shoulder cavity. It provides a new idea and method for clinical application of TCM meridian tendon theory to guide needle knife in the treatment of adhesive shoulder bursitis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合2013年APTA骨科学组临床实践指南《粘连性关节囊炎》诊断标准者; (2)年龄40-65岁,性别不限; (3)主诉中肩关节疼痛和活动受限3月以内者; (4)单侧肩痛,左右不限。 (5)明白知情同意书内容,并自愿签署,能严格遵守本研究方案者。

Inclusion criteria

(1)Those who meet the diagnostic and staging criteria of the 2013 APTA Orthopaedic Group Clinical practice Guide "adhesive bursitis"; (2) 40-65 years old, regardless of gender; (3) those who complain of shoulder pain and limitation of movement within 3 months; (4) unilateral shoulder pain, left or right. (5) those who understand the contents of the informed consent form, sign it voluntarily, and strictly abide by this research scheme.

排除标准:

(1)因其他原因如冠心病、胆囊炎、类风湿性关节炎、系统性红斑狼疮等内科疾病及颈椎病、肩内疾病结核、肿瘤、化脓性关节炎等所引起的肩周疼痛、肩关节活动受限者; (2)合并有其他系统的原发性疾病甚至严重危及生命者; (3)有传染病或严重感染者; (4)糖尿病患者、甲状腺功能减退症患者、凝血功能障碍患者; (5)过敏体质、哺乳或妊娠妇女; (6)具有严重精神疾病患者,如抑郁症、精神分裂症、癫痫患者等。

Exclusion criteria:

(1)Due to other causes, such as coronary heart disease, cholecystitis, rheumatoid arthritis, systemic lupus erythematosus and other medical diseases, as well as cervical spondylosis, shoulder tuberculosis, tumor, suppurative arthritis, etc. (2) those with primary diseases with other systems or even seriously endangering life; (3) infectious diseases or serious infections. (4) patients with diabetes, hypothyroidism, coagulation disorder, (5) allergic constitution, breast-feeding or pregnant women, and (6) patients with serious mental diseases, such as depression, schizophrenia, epilepsy and so on.

研究实施时间:

Study execute time:

From 2021-12-20

To      2022-12-20

征募观察对象时间:

Recruiting time:

From 2021-12-28

To      2022-08-28

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

control group?

Sample size:

干预措施:

肩关节腔内皮质类固醇注射

干预措施代码:

Intervention:

Intracavitary corticosteroid injection of shoulder joint

Intervention code:

组别:

试验组

样本量:

40

Group:

experimental group?

Sample size:

干预措施:

针刀疏筋解结术治疗

干预措施代码:

Intervention:

Needle knife tendon thinning and unknot treatment

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中华人民共和国

省(直辖市):

甘肃省

市(区县):

Country:

China

Province:

Gansu province

City:

单位(医院):

甘肃省中医院

单位级别:

3级甲等医院

Institution/hospital:

Gansu provincial hospital of traditional Chinese medicine

Level of the institution:

Grade 3A Hospital

测量指标:

Outcomes:

指标中文名:

肩关节彩色多普勒超声

指标类型:

主要指标

Outcome:

Color Doppler ultrasound of shoulder joint

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

健康调查简表

指标类型:

次要指标

Outcome:

short form 36 health survey

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简式McGill疼痛量表

指标类型:

主要指标

Outcome:

Simplified McGill pain scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Constant肩关节功能评分量表

指标类型:

主要指标

Outcome:

Constant shoulder function score scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层随机分组法,先按治疗前VAS疼痛评分将预分组的80例患者分为评分4-6分、评分7-10分两个层;评分4-6分患者入组后按就诊先后顺序从01-40编号,对应SPSS软件生成的随机数字和分组编号(试验组编号为“1”,对照组编号为“2”)分别入组,每组各20例;评分7-10分患者入组后按就诊先后顺序从41-80编号,对应SPSS软件生成的随机数字和分组编号(试验组编号为“1”,对照组编为“2”)分别入组,每组各20例;最后将每层内编号为“1”的患者归入试验组,编号为“2”的患者归入对照组,每组各40例。

Randomization Procedure (please state who generates the random number sequence and by what method):

The 80 patients in the pre-treatment group were divided into two levels of 4-6 and 7-10 scores according to the VAS pain score before treatment, and the patients with 4-6 scores in the pre-treatment group were numbered from 01-40 according to the sequence of visits, corresponding to the random number

盲法:

本试验临床治疗操作者知道患者所处的组别,患者也能分辨处自己的治疗方法,故本试验采用单盲法,对临床疗效评价者和数据统计者实施盲法,试验结束后由研究者进行揭盲。试验中如果受试者出现严重不良反应,可由研究者开启应急信封紧急破盲,并在病历观察表中记录打开的原因和日期。

Blinding:

In this trial, the clinical operators know the group of patients, and the patients can distinguish their own treatment methods. Therefore, the single-blind method is used in this trial, at the end of the experiment, the researchers uncovered the blind. In case of severe adverse events, the researcher can open the emergency envelope and record the cause and date of the opening in the chart.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据的采集和管理通过病历记录表完成

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The collection and management of the data is completed by the medical record table

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above